Breast cancer is a highly heterogeneous disease and the clinical outcome strongly correlates with the respective tumor subtype.1 Deregulated apoptosis, mostly via mutations in TP53, is a common driving factor in most tumor diseases.38 Hence, the induction of apoptosis in tumor cells is a highly relevant mechanism in anticancer therapy.14 Currently, there are several strategies for targeting apoptosis in breast cancer immunotherapy and chemotherapy. This evidence concerns the gene TP53 and neoplasm.